_id
690da973ccc777a4e85d084c
Ticker
ACXP
Name
Acurx Pharmaceuticals LLC
Exchange
NASDAQ
Address
259 Liberty Avenue, Staten Island, NY, United States, 10305
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.acurxpharma.com
Description
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia; and CCP, multiple product candidates for gram-positive infections. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Last Close
4.11
Volume
51328
Current Price
4.07
Change
-0.9732360097323608
Last Updated
2025-11-28T11:50:25.600Z
Image
-
Ipo Date
2021-06-25T00:00:00.000Z
Market Cap
7820111
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Rating
4.3333
Target Price
61.7
Strong Buy
1
Buy
2
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
0
Cost Of Revenue
-
Gross Profit
-
Operating Expenses
2028700
Operating Income
-2028700
Interest Expense
-
Pretax Income
-1992790
Net Income
-1992790
Eps
-1.2257251023339206
Dividends Per Share
-
Shares Outstanding
2085363
Income Tax Expense
-
EBITDA
-1992790
Operating Margin
-
Total Other Income Expense Net
35910
Cash
5906802000
Short Term Investments
-
Receivables
-
Inventories
-
Total Current Assets
5906802000
Property Plant Equipment
-
Total Assets
6105211000
Payables
-
Short Term Debt
-
Long Term Debt
-
Total Liabilities
2468175000
Equity
3637036000
Depreciation
-
Change In Working Capital
-228031
Cash From Operations
-1880969
Capital Expenditures
1
Cash From Investing
-
Cash From Financing
1723643
Net Change In Cash
-157326
PE
-
PB
0.0018193458492024826
ROE
-0.054791594034263064
ROA
-0.032640804715840285
FCF
-1880970
Fcf Percent
-
Piotroski FScore
1
Health Score
38
Deep Value Investing Score
5.5
Defensive Investing Score
4.5
Dividend Investing Score
1.5
Economic Moat Investing Score
3.3
Garp Investing Score
1.5
Growth Investing Score
0.5
Momentum Investing Score
2
Net Net Investing Score
8
Quality Investing Score
2
Value Investing Score
4.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
-
Quarters > 0 > income Statement > gross Profit
-
Quarters > 0 > income Statement > operating Expenses
2028700
Quarters > 0 > income Statement > operating Income
-2028700
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-1992790
Quarters > 0 > income Statement > net Income
-1992790
Quarters > 0 > income Statement > eps
-1.2257251023339206
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
1625805
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-1992790
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
35910
Quarters > 0 > balance Sheet > cash
5906802000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
-
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
5906802000
Quarters > 0 > balance Sheet > property Plant Equipment
-
Quarters > 0 > balance Sheet > total Assets
6105211000
Quarters > 0 > balance Sheet > payables
-
Quarters > 0 > balance Sheet > short Term Debt
-
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
2468175000
Quarters > 0 > balance Sheet > equity
3637036000
Quarters > 0 > cash Flow > net Income
-1992790
Quarters > 0 > cash Flow > depreciation
-
Quarters > 0 > cash Flow > change In Working Capital
-228031
Quarters > 0 > cash Flow > cash From Operations
-1880969
Quarters > 0 > cash Flow > capital Expenditures
1
Quarters > 0 > cash Flow > cash From Investing
-
Quarters > 0 > cash Flow > cash From Financing
1723643
Quarters > 0 > cash Flow > net Change In Cash
-157326
Quarters > 0 > ratios > PE
-1.2257251023339206
Quarters > 0 > ratios > PB
0.0018193458492024826
Quarters > 0 > ratios > ROE
-0.054791594034263064
Quarters > 0 > ratios > ROA
-0.032640804715840285
Quarters > 0 > ratios > FCF
-1880970
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
38
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
0
Quarters > 1 > income Statement > cost Of Revenue
-
Quarters > 1 > income Statement > gross Profit
-
Quarters > 1 > income Statement > operating Expenses
2269683
Quarters > 1 > income Statement > operating Income
-2269683
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-2246279
Quarters > 1 > income Statement > net Income
-2246279
Quarters > 1 > income Statement > eps
-1.8872075653677414
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
1190266
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-2269683
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
23404
Quarters > 1 > balance Sheet > cash
6064128
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
40208
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
6157858
Quarters > 1 > balance Sheet > property Plant Equipment
-
Quarters > 1 > balance Sheet > total Assets
6157858
Quarters > 1 > balance Sheet > payables
-
Quarters > 1 > balance Sheet > short Term Debt
-
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
2591527
Quarters > 1 > balance Sheet > equity
3566331
Quarters > 1 > cash Flow > net Income
-2246279
Quarters > 1 > cash Flow > depreciation
-
Quarters > 1 > cash Flow > change In Working Capital
165309
Quarters > 1 > cash Flow > cash From Operations
-1670574
Quarters > 1 > cash Flow > capital Expenditures
4
Quarters > 1 > cash Flow > cash From Investing
-
Quarters > 1 > cash Flow > cash From Financing
3090815
Quarters > 1 > cash Flow > net Change In Cash
1420241
Quarters > 1 > ratios > PE
-1.8872075653677414
Quarters > 1 > ratios > PB
1.3583659564970274
Quarters > 1 > ratios > ROE
-62.985712767547376
Quarters > 1 > ratios > ROA
-36.478252665131286
Quarters > 1 > ratios > FCF
-1670578
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
39
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
-
Quarters > 2 > income Statement > gross Profit
-
Quarters > 2 > income Statement > operating Expenses
2149193
Quarters > 2 > income Statement > operating Income
-2149193
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-2149193
Quarters > 2 > income Statement > net Income
-2149193
Quarters > 2 > income Statement > eps
-2.1450102300514
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
1001950
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-2149193
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
-
Quarters > 2 > balance Sheet > cash
4643887
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
-
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
4805461
Quarters > 2 > balance Sheet > property Plant Equipment
-
Quarters > 2 > balance Sheet > total Assets
4805461
Quarters > 2 > balance Sheet > payables
-
Quarters > 2 > balance Sheet > short Term Debt
-
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
2494062
Quarters > 2 > balance Sheet > equity
2311399
Quarters > 2 > cash Flow > net Income
-2149193
Quarters > 2 > cash Flow > depreciation
2149193
Quarters > 2 > cash Flow > change In Working Capital
-345984
Quarters > 2 > cash Flow > cash From Operations
-2051499
Quarters > 2 > cash Flow > capital Expenditures
0
Quarters > 2 > cash Flow > cash From Investing
-
Quarters > 2 > cash Flow > cash From Financing
2988673
Quarters > 2 > cash Flow > net Change In Cash
937174
Quarters > 2 > ratios > PE
-2.1450102300514
Quarters > 2 > ratios > PB
1.7642719841965842
Quarters > 2 > ratios > ROE
-92.98234532419544
Quarters > 2 > ratios > ROA
-44.723971331782735
Quarters > 2 > ratios > FCF
-2051499
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
33
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
0
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
-
Quarters > 3 > income Statement > operating Expenses
2781791
Quarters > 3 > income Statement > operating Income
-2781791
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-2781791
Quarters > 3 > income Statement > net Income
-2781791
Quarters > 3 > income Statement > eps
-3.266738300745699
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
851550
Quarters > 3 > income Statement > income Tax Expense
4378000
Quarters > 3 > income Statement > EBITDA
-2781791
Quarters > 3 > income Statement > operating Margin
-
Quarters > 3 > income Statement > total Other Income Expense Net
-2781791
Quarters > 3 > balance Sheet > cash
3706713
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
51127
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
3857963
Quarters > 3 > balance Sheet > property Plant Equipment
-
Quarters > 3 > balance Sheet > total Assets
3857963
Quarters > 3 > balance Sheet > payables
-
Quarters > 3 > balance Sheet > short Term Debt
-
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
3242842
Quarters > 3 > balance Sheet > equity
615121
Quarters > 3 > cash Flow > net Income
-2781791
Quarters > 3 > cash Flow > depreciation
2781791
Quarters > 3 > cash Flow > change In Working Capital
-6978
Quarters > 3 > cash Flow > cash From Operations
-2250398
Quarters > 3 > cash Flow > capital Expenditures
0
Quarters > 3 > cash Flow > cash From Investing
-
Quarters > 3 > cash Flow > cash From Financing
194547
Quarters > 3 > cash Flow > net Change In Cash
-2055851
Quarters > 3 > ratios > PE
-3.266738300745699
Quarters > 3 > ratios > PB
5.6343524282214394
Quarters > 3 > ratios > ROE
-452.23476356684296
Quarters > 3 > ratios > ROA
-72.10517571060169
Quarters > 3 > ratios > FCF
-2250398
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-
Quarters > 3 > health Score
20
Valuation > metrics > PE
-1.2257251023339206
Valuation > metrics > PB
0.0018193458492024826
Valuation > final Score
70
Valuation > verdict
99.8% Undervalued
Profitability > metrics > ROE
-0.054791594034263064
Profitability > metrics > ROA
-0.03373720669831154
Profitability > final Score
15
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.6786226476724454
Risk > final Score
68
Risk > verdict
High
Liquidity > final Score
50
Liquidity > verdict
Weak
Prev Valuations > 0
80
Prev Valuations > 1
80
Prev Valuations > 2
23.656475717785604
Prev Profitabilities > 0
15
Prev Profitabilities > 1
15
Prev Profitabilities > 2
15
Prev Risks > 0
-340
Prev Risks > 1
50
Prev Risks > 2
26
Prev Liquidities > 0
50
Prev Liquidities > 1
50
Prev Liquidities > 2
50
Updated At
2025-12-14T00:11:52.170Z
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia; and CCP, multiple product candidates for gram-positive infections. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Stock Price
$ 0.00
0% decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AFed Meeting: How buyback programs support SLV stock - July 2025 Decliners & Low Risk Growth Stock Ideas moha.gov.vn
Read more →Fed Meeting: Will ACXP stock benefit from automation - Trade Volume Report & Precise Swing Trade Alerts moha.gov.vn
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
BUY
Target Price:
$61.7
Analyst Picks
Strong Buy
1
Buy
2
Hold
0
Sell
0
Strong Sell
0
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Debt to Equity
-
Medium
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 7.57% of the total shares of Acurx Pharmaceuticals LLC
1.
Armistice Capital, LLC(3.4028%)
since
2025/06/30
2.
Prospect Financial Services Llc(0.9363%)
since
2025/06/30
3.
Geode Capital Management, LLC(0.4619%)
since
2025/06/30
4.
Vanguard Group Inc(0.4592%)
since
2025/06/30
5.
Morgan Stanley - Brokerage Accounts(0.3351%)
since
2025/06/30
6.
Renaissance Technologies Corp(0.277%)
since
2025/06/30
7.
CAMBRIDGE Invest RESEARCH ADVISORS, INC.(0.2682%)
since
2025/06/30
8.
Susquehanna International Group, LLP(0.22%)
since
2025/06/30
9.
O'Brien Greene & Co., Inc(0.1893%)
since
2025/06/30
10.
Vanguard Capital Wealth Advisors(0.1451%)
since
2025/06/30
11.
ACT Advisors, LLC(0.145%)
since
2025/06/30
12.
State Street Corp(0.1371%)
since
2025/06/30
13.
UBS Group AG(0.1223%)
since
2025/06/30
14.
Nbc Securities Inc(0.0947%)
since
2025/06/30
15.
Jane Street Group LLC(0.0884%)
since
2025/06/30
16.
Northern Trust Corp(0.0861%)
since
2025/06/30
17.
GPS Wealth Strategies Group, LLC(0.0741%)
since
2025/06/30
18.
Baader Bank INC(0.0517%)
since
2025/06/30
19.
Group One Trading, LP(0.0429%)
since
2025/06/30
20.
Wealthcare Advisory Partners LLC(0.0364%)
since
2025/06/30
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.